Phase II trial of sorafenib in patients with recurrent or metastatic squamous cell carcinoma of the head and neck or nasopharyngeal carcinoma.

Purpose: To determine the efficacy and safety of single-agent sorafenib in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck (SCCHN) and nasopharyngeal carcinoma (NPC).

Patients And Methods: In this single-arm phase II trial, oral continuous sorafenib was administered in 28-day cycles. Patients had View Article and Find Full Text PDF